Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 17/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.47 |
| ▸ | ITGAV | P06756 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135904 | 0.97 | ESR1 (0.60) | ESR1ESR2ITGB3ITGA2BITGAV | |
| SCHEMBL6136015 | 0.95 | ESR1 (0.57) | ESR1ESR2ITGB3ITGA2BITGAV | |
| SCHEMBL6136074 | 0.94 | ESR1 (0.61) | ESR1ESR2ITGB3ITGA2B | |
| SCHEMBL6135970 | 0.92 | ESR1 (0.58) | ESR1ESR2ITGB3ITGA2BSLC6A4 | |
| SCHEMBL6136055 | 0.89 | ESR1 (0.58) | ESR1ESR2ITGB3ITGA2B | |
| SCHEMBL6135921 | 0.89 | ESR1 (0.59) | ESR1ESR2ITGB3ITGA2BSLC6A4 | |
| SCHEMBL6135973 | 0.89 | ESR1 (0.58) | ESR1ESR2SLC6A4 | |
| SCHEMBL6136156 | 0.86 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL6136054 | 0.86 | ESR1 (0.63) | ESR1ESR2 | |
| SCHEMBL6135900 | 0.85 | ESR1 (0.62) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | claimed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | claimed |
| WO-1999007377-A1 | 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | disclosed |
| WO-1999007377-A1 | 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | disclosed |